<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140004129A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140004129</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13633575</doc-number><date>20121002</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>47</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>47</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>4241721</main-classification><further-classification>530350</further-classification><further-classification>4241851</further-classification><further-classification>435  724</further-classification><further-classification>800 13</further-classification></classification-national><invention-title id="d0e43">Novel Polypeptides Involved in Immune Response</invention-title><us-related-documents><division><relation><parent-doc><document-id><country>US</country><doc-number>12753819</doc-number><date>20100402</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8309083</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13633575</doc-number></document-id></child-doc></relation></division><division><relation><parent-doc><document-id><country>US</country><doc-number>11359254</doc-number><date>20060221</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>7708993</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>12753819</doc-number></document-id></child-doc></relation></division><division><relation><parent-doc><document-id><country>US</country><doc-number>09728420</doc-number><date>20001128</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>11359254</doc-number></document-id></child-doc></relation></division><continuation-in-part><relation><parent-doc><document-id><country>US</country><doc-number>PCT/US00/01871</doc-number><date>20000127</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>09728420</doc-number></document-id></child-doc></relation></continuation-in-part><continuation-in-part><relation><parent-doc><document-id><country>US</country><doc-number>09264527</doc-number><date>19990308</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>PCT/US00/01871</doc-number></document-id></child-doc></relation></continuation-in-part><continuation-in-part><relation><parent-doc><document-id><country>US</country><doc-number>09244448</doc-number><date>19990203</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>09264527</doc-number></document-id></child-doc></relation></continuation-in-part></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>AMGEN CANADA INC.</orgname><address><city>Mississauga</city><country>CA</country></address></addressbook><residence><country>CA</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>AMGEN INC.</orgname><address><city>Thousand Oaks</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Yoshinaga</last-name><first-name>Steven K</first-name><address><city>Thousand Oaks</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Mak</last-name><first-name>Tak W.</first-name><address><city>Thunder Bay</city><country>CA</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Shahinian</last-name><first-name>Arda</first-name><address><city>Markham</city><country>CA</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Bladt</last-name><first-name>Anna Trafuri</first-name><address><city>Toronto</city><country>CA</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Senaldi</last-name><first-name>Giorgio</first-name><address><city>Thousand Oaks</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>AMGEN CANADA INC.</orgname><role>03</role><address><city>Mississauga</city><country>CA</country></address></addressbook></assignee><assignee><addressbook><orgname>AMGEN INC.</orgname><role>02</role><address><city>Thousand Oaks</city><state>CA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.</p></abstract></us-patent-application>